Masao Iwamori Selected Research

Lewis Y antigen

8/2017	Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression.
6/2015	Lewis y enhances CAM-DR in ovarian cancer cells by activating the FAK signaling pathway and upregulating Bcl-2/Bcl-XL expression.
4/2012	Expression and correlation of Lewis y antigen and TGF-β1 in ovarian epithelial carcinoma.
6/2011	Overexpression of Lewis(y) antigen protects ovarian cancer RMG-1 cells from carboplatin-induced apoptosis by the upregulation of Topo-I and Topo-II β.
2/2011	Enhancive effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-I.
1/2011	Study on the expression and clinical significances of lewis y antigen and integrin αv, β3 in epithelial ovarian tumors.
1/2011	The stimulation of IGF-1R expression by Lewis(y) antigen provides a powerful development mechanism of epithelial ovarian carcinoma.
1/2011	Increase in docetaxel-resistance of ovarian carcinoma-derived RMG-1 cells with enhanced expression of Lewis Y antigen.
11/2010	Lewis (y) antigen overexpression increases the expression of MMP-2 and MMP-9 and invasion of human ovarian cancer cells.
7/2010	Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masao Iwamori Research Topics

Disease

18	Carcinoma (Carcinomatosis) 10/2019 - 10/2002
17	Neoplasms (Cancer) 11/2017 - 10/2002
13	Ovarian Neoplasms (Ovarian Cancer) 11/2017 - 11/2003
6	Endometrial Neoplasms (Endometrial Cancer) 01/2019 - 10/2003
5	Adenocarcinoma 01/2017 - 10/2002
4	Ovarian Epithelial Carcinoma 08/2017 - 01/2011
4	Neoplasm Metastasis (Metastasis) 01/2011 - 10/2003
3	Endometrioid Carcinoma 01/2015 - 01/2010
3	Zellweger Syndrome (Zellweger's Syndrome) 09/2013 - 05/2007
3	Inflammation (Inflammations) 03/2008 - 08/2006
2	Clear Cell Adenocarcinoma 01/2015 - 11/2010
2	Serous Cystadenocarcinoma 01/2015 - 11/2010
2	Peroxisome biogenesis disorders 06/2007 - 01/2004
2	Ulcer 08/2006 - 02/2005
2	Breast Neoplasms (Breast Cancer) 01/2005 - 10/2003
1	Guillain-Barre Syndrome 10/2016
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2016
1	Peripheral Nervous System Diseases (PNS Diseases) 10/2016
1	Necrosis 06/2015
1	Mucinous Cystadenocarcinoma 01/2015
1	Diarrhea 12/2013
1	Infections 10/2008

Drug/Important Bio-Agent (IBA)

13	GlycolipidsIBA 10/2019 - 10/2002
13	Lewis Y antigenIBA 08/2017 - 06/2008
10	LipidsIBA 01/2017 - 01/2004
6	OligosaccharidesIBA 01/2019 - 06/2008
6	Biological ProductsIBA 01/2017 - 11/2003
5	Sulfoglycosphingolipids (Sulfatides)IBA 01/2017 - 02/2005
5	EnzymesIBA 01/2017 - 11/2003
5	Pharmaceutical PreparationsIBA 12/2012 - 01/2005
4	Paclitaxel (Taxol)FDA LinkGeneric 10/2019 - 12/2006
4	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 12/2006
4	AntigensIBA 10/2016 - 10/2002
4	Proteins (Proteins, Gene)FDA Link 12/2012 - 12/2006
3	CeramidesIBA 01/2017 - 12/2006
3	SulfotransferasesIBA 01/2017 - 01/2005
3	GangliosidesIBA 10/2016 - 01/2007
3	IntegrinsIBA 06/2015 - 07/2010
3	Phospholipids (Phosphatides)FDA LinkGeneric 09/2013 - 05/2007
3	Messenger RNA (mRNA)IBA 09/2012 - 01/2008
3	CarbohydratesIBA 01/2011 - 01/2005
2	globotriaosylceramide (globotriosylceramide)IBA 10/2019 - 01/2017
2	GlycosyltransferasesIBA 01/2019 - 09/2012
2	Blood Group Antigens (Blood Groups)IBA 01/2019 - 09/2005
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2017 - 01/2009
2	galactosylceramide sulfotransferaseIBA 01/2017 - 09/2012
2	sulfoglycolipidsIBA 01/2017 - 01/2015
2	Monoclonal AntibodiesIBA 10/2016 - 11/2010
2	Carboplatin (JM8)FDA LinkGeneric 06/2015 - 06/2011
2	cholesteryl sulfateIBA 09/2012 - 08/2006
2	Transforming Growth Factors (Transforming Growth Factor)IBA 04/2012 - 04/2012
2	PlasmalogensIBA 01/2009 - 09/2008
2	Glycerophospholipids (Phosphoglycerides)IBA 01/2009 - 05/2007
2	GlycosphingolipidsIBA 09/2005 - 10/2002
2	Estrogens (Estrogen)FDA Link 01/2005 - 10/2003
1	Polysaccharides (Glycans)IBA 01/2019
1	H antigenIBA 01/2019
1	HMMC-1 monoclonal antibodyIBA 01/2019
1	Therapeutic UsesIBA 11/2017
1	Phosphotransferases (Kinase)IBA 11/2017
1	Glycoproteins (Glycoprotein)IBA 08/2017
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2017
1	phytosphingosineIBA 01/2017
1	CarbonIBA 01/2017
1	globotetraosylceramideIBA 01/2017
1	Polypeptide N-acetylgalactosaminyltransferaseIBA 10/2016
1	IV(4)-galactosyl-N-acetylganglioside GD1aIBA 10/2016
1	I(3)SO3-galactosylceramideIBA 10/2016
1	Apoptosis Regulatory ProteinsIBA 06/2015
1	LactosylceramidesIBA 01/2015
1	CDw17 antigen (lactosylceramide)IBA 01/2015
1	Penicillins (Penicillin)FDA Link 12/2013
1	Streptomycin (Streptomycin Sulfate)FDA Link 12/2013
1	Cholesterol Esters (Cholesteryl Esters)IBA 09/2012
1	CholesterolIBA 09/2012
1	G(M3) GangliosideIBA 09/2012
1	Growth Factor ReceptorsIBA 04/2012
1	Cyclin AIBA 01/2012
1	Cyclin EIBA 01/2012
1	Cyclin D1IBA 01/2012
1	trioctyl phosphine oxide (TOPO)IBA 06/2011
1	Insulin-Like PeptidesIBA 01/2011
1	Docetaxel (Taxotere)FDA Link 01/2011
1	Complementary DNA (cDNA)IBA 11/2010
1	Metalloproteases (Metalloproteinases)IBA 11/2010
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 11/2010
1	Tissue Inhibitor of Metalloproteinase-2IBA 11/2010
1	AcidsIBA 11/2010
1	SugarsIBA 11/2010
1	TransferasesIBA 11/2010
1	AntibodiesIBA 07/2010
1	Fibronectins (Fibronectin)IBA 07/2010
1	Integrin alpha5beta1IBA 07/2010
1	ErbB Receptors (EGF Receptor)IBA 03/2010
1	Collagen Type I (Type I Collagen)IBA 01/2010
1	sulfolipidsIBA 01/2010
1	Ethanolamine (Colamine)IBA 01/2009
1	NeurotoxinsIBA 10/2008

Therapy/Procedure

4	Therapeutics 11/2017 - 01/2005
1	Drug Therapy (Chemotherapy) 06/2011